Can a simple blood test predict sarcoma recurrence?

NCT ID NCT04925089

Recruiting now Knowledge-focused Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Nov 19, 2025 · Last updated May 18, 2026 · Updated 24 times

Summary

This study looks at whether a blood test for tumor DNA (ctDNA) and detailed scans can help predict how well chemotherapy works in people with a rare soft tissue cancer called leiomyosarcoma. About 40 participants will give blood samples and have scans before, during, and after treatment. The goal is to find better ways to spot early signs of cancer returning, not to test a new treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Mayo Clinic
RECRUITING

Rochester, Minnesota, 55901, United States

Contact
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States

Contact Phone: •••-•••-••••
Vanderbilt University Medical Center
RECRUITING

Nashville, Tennessee, 37232, United States

Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.

LEIOMYOSARCOMA